Systems and methods for gene therapy via administration of genetically modified viral vectors

A recombinant CMV viral vector comprising:

• one or more exogenous donor genes selected from a human telomerase reverse transcriptase (hTERT) gene, a human follistatin-344 (hFST) gene, a klotho (KL) gene, a damage suppressor (Dsup) gene, a peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1-α) gene, an octamer-binding transcription factor 4 (Oct-4) gene, a sex determining region Y-box 2 (Sox2) gene, and a Krüppel-like factor 4 (KLF4) gene,
• wherein the one or more exogenous donor genes are fused to a native CMV gene selected from the IE1 gene, pp65 gene, and gB gene,
• wherein the one or more exogenous donor genes are fused to a native CMV gene via a sequence coding for a 2A self-cleaving peptide, and
• wherein the viral vector comprises a bacterial artificial chromosome (BAC) in which the one or more exogenous donor genes are disposed.